Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Shree Ganesh Biotech (India) Ltd operates in Biotechnology within the Healthcare sector.
Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
No scheme among the 32 fund houses on record reported a position in Shree Ganesh Biotech (India) Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Anthem Biosciences LimitedANTHEMANTHEM | ₹48,213 Cr | ₹48,264 Cr | ₹2,002 Cr | ₹793 Cr | 39.3% | ₹576 Cr | 27.9% | 27.6% | 19.5% | 124 |
| Advanced Enzyme Technologies LimitedADVENZYMESADVENZYMES | ₹3,072 Cr | ₹3,092 Cr | ₹750 Cr | ₹224 Cr | 30.7% | ₹166 Cr | 23.3% | 13.7% | 11.1% | 331 |
| CCME Global LtdCCMECCME | ₹54 Cr | ₹54 Cr | ₹0 Cr | ₹0 Cr | — | ₹4 Cr | — | -2.9% | -2.9% | — |
| Vivo Bio Tech LtdVIVOBIOTVIVOBIOT | ₹38 Cr | ₹92 Cr | ₹47 Cr | ₹21 Cr | 44% | ₹7 Cr | 15.6% | 15.2% | 11% | 517 |
| Shree Ganesh Biotech (India) LtdSHREEGANESSHREEGANES | ₹19 Cr | ₹19 Cr | ₹23 Cr | ₹-1 Cr | -19.3% | ₹0 Cr | 7.7% | 0.8% | 0.6% | 846 |
| Genomic Valley Biotech LtdGVBLGVBL | ₹9 Cr | ₹9 Cr | ₹0 Cr | ₹-0 Cr | 14.8% | ₹-1 Cr | 11.1% | 1% | 0.8% | 3,565 |
Documents link to external sources (exchange filings, company investor pages).
Standalone figures
| Ratio | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross margin % | — | — | 5.1% | 5.2% | 4.5% | 1.2% | 1.4% | -1.8% |
| Holder (%) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 2.17% | 2.17% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | 1.42% | |
| DII | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| 97.83% | 97.83% | 98.58% | 98.58% | 98.58% | 98.58% | 98.58% | 98.58% | 98.58% | 98.58% | 98.58% | 98.58% | |
| No. of shareholders | — | — | — | — | — | — | — | — | 1,89,375 | 1,86,148 | 1,83,658 | 1,81,722 |
| EBITDA margin % | 30.5% | 9.3% | 4.1% | 4.7% | 3.4% | -1% | -4.6% | -19.3% |
| EBIT margin % | 30.5% | 9.3% | 4.1% | 4.7% | 3.4% | -1% | -4.6% | -19.3% |
| PAT margin % | 30.5% | 9.7% | 1.9% | 3.5% | 3.3% | 3.1% | 1.2% | 7.7% |
| Working capital | ||||||||
| Receivable days | — | — | 601 | 221 | 113 | 59 | 0 | 0 |
| Inventory days | — | — | 0 | 0 | 0 | 0 | 47 | 846 |
| Payable days | — | — | 369 | 171 | 101 | 189 | 0 | 0 |
| NWC days | — | — | 232 | 49 | 12 | -129 | 47 | 846 |
| Leverage | ||||||||
| Current ratio | — | — | 4.3 | 2.72 | 4.63 | 0.35 | 54.52 | 70 |
| Debt to EBITDA | — | — | 0.27 | 0 | 0 | — | — | — |
| Debt to equity | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest coverage | — | — | — | — | — | — | — | — |
| Asset turnover | — | — | 0.23 | 0.78 | 0.79 | 0.28 | 0.36 | 0.08 |
| Return ratios | ||||||||
| Return on assets % | — | — | 0.4% | 2.7% | 2.6% | 0.8% | 0.4% | 0.6% |
| Return on capital employed % | — | — | 1.2% | 5.9% | 4.4% | 1.4% | 0.6% | 0.8% |
| Return on equity % | — | — | 0.6% | 4.2% | 3.3% | 1% | 0.4% | 0.6% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Promoter holding up 0 percentage points since Sep 2023.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 27 Mar 2024 | NEW ERA FUND LIMITED | Bulk | BSE | Sell | 30,00,000 | ₹1.10 | ₹0.33 Cr |
| 8 Jan 2024 | TOPGAIN FINANCE PRIVATE LIMITED | Bulk | BSE | Sell | 29,58,016 | ₹1.47 | ₹0.43 Cr |
| 8 Jan 2024 | TOPGAIN FINANCE PRIVATE LIMITED | Bulk | BSE | Buy | 5,00,000 | ₹1.47 | ₹0.07 Cr |
| 5 Jan 2024 | TOPGAIN FINANCE PRIVATE LIMITED | Bulk | BSE | Sell | 86,37,984 | ₹1.56 | ₹1.35 Cr |
| 4 Jan 2024 | TOPGAIN FINANCE PRIVATE LIMITED | Bulk | BSE | Buy | 1,15,96,000 | ₹1.49 | ₹1.73 Cr |
| 4 Jan 2024 | SHRI CHAND | Bulk | BSE | Sell | 30,12,000 | ₹1.48 | ₹0.45 Cr |
| 4 Jan 2024 | SETU SECURITIES PVT. LTD. | Bulk | BSE | Buy | 25,68,661 | ₹1.48 | ₹0.38 Cr |
| 20 Dec 2023 | ASHOK KUMAR | Bulk | BSE | Buy | 44,10,000 | ₹1.33 | ₹0.59 Cr |
| 14 Dec 2023 | NATTAYA CHOWDHURY | Bulk | BSE | Sell | 60,00,000 | ₹1.11 | ₹0.67 Cr |
| 14 Dec 2023 | SHRI CHAND | Bulk | BSE | Buy | 26,60,000 | ₹1.14 | ₹0.30 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Closure of Trading Window
Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Regulations 30, 33 And Other Applicable Provisions Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Board Meeting Outcome for Outcome Of The Board Meeting Of The Board Held On 29Th January 2026.
Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window
| Date | Category | Subject | Filing |
|---|---|---|---|
| 6 Apr 2026, 6:43 pm | Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | |
| 17 Mar 2026, 6:09 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window | |
| 29 Jan 2026, 4:31 pm | Company Update Reg. 32 (1), (3) - Statement of Deviation & Variation | Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 | |
| 29 Jan 2026, 4:27 pm | Result Financial Results | Regulations 30, 33 And Other Applicable Provisions Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 | |
| 29 Jan 2026, 4:13 pm | Board Meeting Outcome of Board Meeting | Board Meeting Outcome for Outcome Of The Board Meeting Of The Board Held On 29Th January 2026. | |
| 19 Jan 2026, 5:57 pm | Board Meeting | Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting. | |
| 5 Jan 2026, 1:40 pm | Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | |
| 20 Dec 2025, 12:44 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window |
| ₹ Cr | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 | 8 | 6 | 2 | 17 | 73 | 62 | 20 | 23 | 5 | |
| COGS | -4 | -3 | -3 | -2 | 16 | 69 | 60 | 20 | 23 | 5 |
| Gross profit | — | — | — | — | 1 | 4 | 3 | 0 | 0 | -0 |
| 9 | 8 | 7 | 4 | 0 | 0 | 1 | 0 | 1 | 1 | |
| 4 | 4 | 2 | 0 | 1 | 3 | 2 | -0 | -1 | -1 | |
| OPM % | 44.3% | 44.5% | 30.5% | 9.3% | 4.1% | 4.7% | 3.4% | -1% | -4.6% | -19.3% |
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| — | — | — | — | -0 | 0 | 1 | 1 | 1 | 1 | |
| Profit before tax | 4 | 4 | 2 | 0 | 0 | 4 | 3 | 1 | 0 | 1 |
| Tax | — | — | — | — | 0 | 1 | 1 | 0 | 0 | 0 |
| Tax % | — | — | — | — | 25.6% | 27.7% | 25.1% | 27.1% | 28.2% | 27.5% |
| 4 | 4 | 2 | 0 | 0 | 3 | 2 | 1 | 0 | 0 | |
| PAT margin % | 43.7% | 44.5% | 30.5% | 9.7% | 1.9% | 3.5% | 3.3% | 3.1% | 1.2% | 7.7% |
| EPS (₹) | — | 19.1 | 1.8 | 0.1 | 0.2 | 0.1 | 0.1 | 0 | 0 | 0 |
| EPS adjusted (₹) | — | — | — | — | 0 | 0.1 | 0.1 | 0 | 0 | 0 |
| Annual report | Annual report for Mar 2017 | Annual report for Mar 2018 | Annual report for Mar 2019 | Annual report for Mar 2020 | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 20 | 20 | 40 | 40 | 40 | 40 |
| Reserves | 38 | 40 | 22 | 23 | 23 | 24 |
| Minority interest | — | — | 0 | — | 0 | — |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 17 | 33 | 17 | 11 | 0 | 0 | |
| Total equity & liabilities | 75 | 94 | 80 | 74 | 63 | 64 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 3 | 3 | 0 | 0 | 9 | 9 |
| 72 | 90 | 80 | 74 | 54 | 55 | |
| Total assets | 75 | 94 | 80 | 74 | 63 | 64 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 3 | 0 | -3 | 10 | -10 | -8 | |
| -3 | -0 | 3 | -10 | 10 | 8 | |
| 0 | -0 | 0 | 0 | 0 | 0 | |
| Net cash flow | 0 | 0 | 0 | -0 | -0 | -0 |
| Free cash flow | 3 | 0 | -3 | 10 | -10 | -8 |
| CFO / Operating profit % | 438.6% | 10.5% | -129.4% | — | — | — |